Other languages BriaCell Therapeutics Corp.

Equities

BCT

CA1079301091

Market Closed - Toronto S.E. Other stock markets 03:59:51 2024-05-13 pm EDT			5-day change	1st Jan Change
2.99 ^CAD	-1.64%		-1.64%	-61.67%

Apr. 24	BriaCell Therapeutics to Present Bria-IMT Phase 2 Findings at American Society of Clinical Oncology Annual Meeting	MT
Apr. 10	BriaCell 2024 AACR Preclinical Poster Confirms Strong Anti-Cancer Activity of Bria-OTS+? and Bria-PROS+? Clinical Candidates for Breast and Prostate Cancer	CI

Other languages

Unlock all the news on all businesses: Never miss an investment opportunity again!

100% Free Registration

BriaCell 2024 AACR Preclinical Poster Confirms Strong Anti-Cancer Activity of Bria-OTS+? and Bria-PROS+? Clinical Candidates for Breast and Prostate Cancer	Apr. 10
BriaCell to Showcase Latest Bria-IMT Data in Poster Presentations at 2024 AACR	Apr. 09
BriaCell Therapeutics Corp. Reports Earnings Results for the Second Quarter and Six Months Ended January 31, 2024	Mar. 18
BriaCell to Present Clinical Data in CNS Metastasis and Antibody-Drug Conjugate Resistant Breast Cancer at AACR Conference	Mar. 06
BriaCell Therapeutics Corp. Announces Strong Clinical Data in Breast Cancer Patients; Reports Another Notable Responder Case	Feb. 07
Briacell Therapeutics Corp. Announces Lead Prostate Cancer Candidate Bria-Pros+, Initiates Gmp Manufacturing	Feb. 06
BriaCell Images Confirm Robust Anti-Tumor Activity in Patient with "Eye-Bulging" Metastatic Breast Cancer	Jan. 04
BriaCell Has Reports 71% Central Nervous System Response Rate in Advanced Breast Cancer Patients	Dec. 28
BriaCell Therapeutics Corp. Reports 71% Central Nervous System Response Rate in Advanced Breast Cancer Patients	Dec. 28
BriaCell Therapeutics Corp. Reports Unprecedented Preliminary Survival and Clinical Benefit in Antibody-Drug Conjugate Refractory Patient Subset	Dec. 20
BriaCell Therapeutics Corp. Reports Earnings Results for the First Quarter Ended October 31, 2023	Dec. 14
BriaCell Highlights Topline Survival and Clinical Benefit Data in Advanced Metastatic Breast Cancer at Breast Cancer Symposium	Dec. 06
BriaCell Therapeutics Corp. Highlights Outstanding Topline Survival and Clinical Benefit Data in Advanced Metastatic Breast Cancer at the 2023 SABCS	Dec. 06
BriaCell Therapeutics Corp. Announces Anew Remarkable Responder in Phase 2 Study of the Bria-IMT Combination Regimen	Nov. 30
BriaCell Reports Unprecedented Anti-Tumor Activity of its Next Generation Personalized Breast and Prostate Cancer Immunotherapies in Tumor Models at the 2023 SITC Annual Meeting; FDA Greenlights Bria-OTS? IND	Nov. 03
Top Premarket Gainers	23-10-31
BriaCell Therapeutics Corp. Reports Earnings Results for the Full Year Ended July 31, 2023	23-10-25
BriaCell Forms Medical Advisory Board of Breast Cancer Specialists to Advance Lead Oncology Candidate	23-10-25
BriaCell Therapeutics Corp. Forms Medical Advisory Board of Distinguished Breast Cancer Specialists to Advance its Lead Oncology Candidate	23-10-25
BriaCell Announces Presentations at 2023 Society for the Immunotherapy of Cancer, San Antonio Breast Cancer, Conferences	23-10-18

No results for this search

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Other languages BriaCell Therapeutics Corp.

Equities

BCT

CA1079301091

Other languages

Filters